Advanced-stage Cancer can be Treated by a Novel Antibody Drug

Academy Research Fellow Maija Hollmén’s research group has searched for means of altering the activity of macrophages in order to direct the immune defense to attack cancer. The antibody bexmarilimab, developed based on this research and in collaboration with Faron Pharmaceuticals, is currently undergoing clinical trials in patients. Hollmén’s group has studied the changes occurring in the defense systems of patients with cancer following antibody treatment.

In the majority of patients, the antibody treatment activated killer T cells, which are the body’s strike force against cancer. Additionally, the antibody treatment successfully lowered the suppressive potential of macrophage precursors travelling in the blood circulation. The patients also showed increases in certain mediators of inflammation and types of white blood cell in the blood, describes Hollmén.

The activation of the killer T cells is a very promising demonstration of the antibody’s capability to boost the defense system against cancer. The treated patients had very advanced and poorly treatable cancers, which highlights the significance of the results, says Doctoral Candidate Jenna Rannikko.

Bexmarilimab May Benefit Patients for Whom Current Treatment Options Are Ineffective
The research also yielded new information on the mode of action of bexmarilimab. The antibody binds the molecule Clever-1 present on macrophages and alters its function.

Clever-1 transports material needless to the body inside macrophages to be degraded. Objects disposed in this manner are swept under the rug, in a manner of speaking. This kind of concealment is beneficial for the body’s natural balance and helps to avoid stirring the immune defense unnecessarily.

However, cells originating from cancer should be detected. When the antibody is used to block Clever-1 from performing its cleaning job, it facilitates the activation of cells of the immune defense. This in part leads to the waking up of the T cells in patients, describes Doctoral Candidate Miro Viitala.

There is demand for treatments that boost the activity of the immune defense since the current options on the market only help some patients.

Bexmarilimab’s mode of action is different from the drug treatments against cancer currently on the market. Therefore, it can be beneficial for patients for whom current treatment options are ineffective, concludes Postdoctoral Researcher Reetta Virtakoivu.

Source: Medindia